Categories: News

Verantos Named to Inc. 5000 List for the Third Consecutive Year

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Global leader in high-validity real-world evidence for life sciences grows more than 3x in three years

PALO ALTO, Calif., Aug. 16, 2024 /PRNewswire/ — Verantos, the global leader in high-validity real-world evidence (RWE) for the life sciences, marks its third consecutive appearance on the Inc. 5000, ranking No. 1393 on the annual list of the fastest-growing private companies in America. The prestigious Inc. 5000 provides a data-driven look at the most successful independent and entrepreneurial businesses in the U.S. Past honorees including Microsoft, Meta, Chobani, and Under Armour.

Verantos is the only RWE company to earn a spot on the Inc. 5000 list this year.

Verantos’ appearance on the Inc. 5000 underscores the rapid adoption of high-validity real-world evidence and Verantos’ commitment to providing life sciences organizations with rich and reliable real-world data (RWD) through advanced curation, linkage, and enrichment.

“Our sustained growth reflects the value we deliver to our clients, including by providing them with the rich and reliable real-world data they need to advance groundbreaking treatments,” said Dan Riskin, Verantos CEO. “We are honored to be recognized alongside many other dynamic and entrepreneurial companies for the third consecutive year.”

Inc. reports the Inc. 5000 class of 2024 represents companies that have driven rapid revenue growth while navigating inflationary pressure, the rising costs of capital, and seemingly intractable hiring challenges.

About Verantos
Verantos is the global leader in high-validity real-world evidence at scale. By applying artificial intelligence to the complete patient record, Verantos enables life sciences organizations to generate high-validity evidence across therapeutic areas with measured accuracy, completeness, and traceability. Credible evidence accelerates clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives. For more information, visit Verantos.com or follow us on LinkedIn.

Media Contact
Smriti Shakargaye for Verantos
prforverantos@bospar.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/verantos-named-to-inc-5000-list-for-the-third-consecutive-year-302223952.html

SOURCE Verantos

Staff

Recent Posts

InstantGMP™ Announces Major Enhancements to GMP Certification Resource Center

CARY, N.C., Aug. 13, 2025 /PRNewswire/ -- InstantGMP™, a leading provider of software solutions for…

26 minutes ago

MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability.Operating Expenses Cut…

26 minutes ago

Nursing Homes See Measurable Results and Rising Excitement Over Advanced AI Tool from Long-Term Care Tech Firm

CMI.ai by Blue Purpose — the first AI solution within the VIBE platform built to…

27 minutes ago

Colossal launches first-of-its-kind “Style Icon” competition in support of the Elton John AIDS Foundation

Presented by Elton John, David Furnish, and Charlotte Tilbury One trendsetter will attend Versace's 2026…

27 minutes ago

HopeAI Showcases AI-Powered Synthetic Data to Speed Up Cancer Drug Trials at ASCO 2025

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- HopeAI , a Mayo Clinic Platform Accelerate company,…

27 minutes ago